Ewing Sarcoma Drugs Market: By Tumour Type, By Drug Type, By Application, By End User And Geography

Ewing Sarcoma Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Tumour Type (Bone Tumour, Peripheral Primitive Neuroectodermal Tumour, Askin Tumour, Soft Tissue Tumour), By Drug Type (Vincristine, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Dactinomycin), By Application (Chemotherapy, Surgery, Radiation therapy, Immuno-therapy and Others), By End User (Hospital and Clinics, Cancer Treating Centres and Others) And Region

Ewing Sarcoma Drugs Market size was valued at US$ 286.3 million in 2023 and is poised to grow at a CAGR of 5.6% from 2024-2030. Ewing Sarcoma is a rare type of cancer that occurs in bones or the soft tissue around the bones. It primarily affects children and young adults, with the majority of cases diagnosed in adolescents during their second decade of life. Commonly affects long bones such as the femur, tibia, and humerus, as well as the pelvis. The desire for new and improved medications is fueled by the high death rate, even though a rare disease the increasing prevalence of incidence rates, increasing investments from both government and private research institutions, and growing healthcare expenditure are driving the market expansion. Emerging new therapeutic approaches Personalised medicine, immunotherapies, and targeted therapeutics are changing how Ewing sarcoma is treated. The number of incidences of Ewing Sarcoma is around 1200 for the year 2023 globally, thus owing to the fewer number of patients the expansion of Ewing sarcoma market is not considered as the main priority of companies. It can be expensive to develop medications for uncommon illnesses like Ewing sarcoma. Due to the small market, the prospective return on investment may be unknown, and the costs of research, clinical trials, and regulatory approval are considerably high compared to other markets.

Regulatory standards for drug approval are time-consuming for uncommon diseases with tiny patient groups. Moreover, development of targeted therapies for Ewing sarcoma is a key opportunity for the market players. For instance, Gradalis is developing and testing Vigil, a fully personalized, patient-specific cancer immunotherapy that can be applied to virtually any cancer. Vigil utilizes the patient’s own cancer cells to create a fully personalized cancer immunotherapy. In addition, Oncternal Therapeutics ONCT-216 (formerly called TK216) is a first-in-class small molecule inhibiting the biological activity of the ETS family. It is currently being evaluated in the Phase II portion of a study in patients with relapsed or refractory Ewing sarcoma.

Ewing Sarcoma Drugs Market Key Developments:

  • In July 2023, GlaxoSmithKline plc publicised that the Niraparib drug was under clinical development and is currently in Phase II for Ewing Sarcoma and is formulated as hard gelatin capsules, tablets, and film-coated tablets for oral administration.
  • In April 2023, Sumitomo Pharma Oncology, Inc. announced that TP-1287, an investigational oral drug CDK9 inhibitor, has received orphan drug designation from the FDA for the treatment of patients with Ewing sarcoma.
  • In April 2022, AI Therapeutics announced the acquisition of Entre Chem’s, investigational drug candidate EC-8042 (redesignated AIT-102), a novel targeted cancer therapy in development for cancers including pediatric tumours, rhabdoid tumours and Ewing sarcoma.

Ewing Sarcoma Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.6%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Ewing Sarcoma Drugs Market Dynamics

The prognosis for Ewing sarcoma has improved over the years due to advances in treatment. The 5-year survival rate for localized Ewing sarcoma is around 70–80%, while the survival rate for metastatic disease is lower, around 30–40%. It is noted that survival rates have significantly increased. National Comprehensive Cancer Network (NCCN) recommended different chemotherapy combinations to treat localized and metastatic Ewing sarcoma. VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide), VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin), and VIDE (vincristine, ifosfamide, doxorubicin, and etoposide) are recommended by NCCN in the first line and as primary therapy for metastatic disease at initial presentation. For second-line treatment Cyclophosphamide and topotecan, Irinotecan + temozolomide ± NCCN recommends Vincristine, Ifosfamide, carboplatin, etoposide, and Lurbinectedin. In all the treatment plans only the 6 drugs are present, indicating the success of the Ewing Sarcoma market is based on the 6 main drugs available and also the market can expect upcoming new therapies such as stem cell therapy, T–cell therapy and so on. This gap remains a huge opportunity for companies to tap in.

Ewing Sarcoma Drugs Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 286.3 million

Market CAGR

5.6%

By Tumour Type

  • Bone Tumour
  • Peripheral Primitive Neuroectodermal Tumour
  • Askin Tumour
  • Soft Tissue Tumour

By Drug Type

  • Vincristine
  • Cyclophosphamide
  • Doxorubicin
  • Etoposide
  • Ifosfamide
  • Dactinomycin

By Application

  • Chemotherapy
  • Surgery
  • Radiation therapy
  • Others

By End Users

  • Hospital and Clinics
  • Cancer Treating Centres
  • Others

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.

Download Free Sample Report

Frequently Asked Questions

The Ewing Sarcoma Drugs Market size was valued at US$ 286.3 million in 2023 and is poised to grow at a CAGR of 5.6% from 2024-2030.

Major companies operating within the Ewing Sarcoma Drugs Market are Eli Lilly, Merck, GlaxoSmithKline, Johnson & Johnson, Novartis, Sanofi, Pfizer Inc. and F. Hoffmann-La Roche Ltd. (Roche).

Rising cases of Ewing Sarcoma particularly among adolescents, Progress in medical technology and the development of novel therapies, such as targeted therapies and immunotherapies, Increased investment in research and development and Advances in diagnostic techniques have led to early detection are the main drivers of the Ewing Sarcoma market.

North America, particularly the United States, leads in the Ewing Sarcoma Drugs Market due to the prevalence of presence of research institutions, universities, and biotechnology companies with significant investments in R&D activities

Hospitals and Hospitals and Clinics dominate other segments in the Ewing Sarcoma Drugs Market.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Ewing Sarcoma Drugs Market Introduction 
2.1.Global Ewing Sarcoma Drugs Market  - Taxonomy
2.2.Global Ewing Sarcoma Drugs Market  - Definitions
2.2.1.Tumour Type 
2.2.2.Drug Type 
2.2.3.Application
2.2.4.End Users
2.2.5.Region
3.Global Ewing Sarcoma Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Ewing Sarcoma Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Ewing Sarcoma Drugs Market  By Tumour Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Bone Tumour
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Peripheral Primitive Neuroectodermal Tumour
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Askin Tumour
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Soft Tissue Tumour
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Ewing Sarcoma Drugs Market  By Drug Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Vincristine
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Cyclophosphamide
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Doxorubicin
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Etoposide
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Ifosfamide
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Dactinomycin
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
7.Global Ewing Sarcoma Drugs Market  By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Chemotherapy
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Surgery
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Radiation therapy
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Ewing Sarcoma Drugs Market  By End Users, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Hospital and Clinics
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Cancer Treating Centres
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Others
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Ewing Sarcoma Drugs Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Ewing Sarcoma Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Tumour Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Bone Tumour
10.1.2.Peripheral Primitive Neuroectodermal Tumour
10.1.3.Askin Tumour
10.1.4.Soft Tissue Tumour
10.2.  Drug Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Vincristine
10.2.2.Cyclophosphamide
10.2.3.Doxorubicin
10.2.4.Etoposide
10.2.5.Ifosfamide
10.2.6.Dactinomycin
10.3.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Chemotherapy
10.3.2.Surgery
10.3.3.Radiation therapy
10.3.4.Others
10.4.  End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital and Clinics
10.4.2.Cancer Treating Centres
10.4.3.Others
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Ewing Sarcoma Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Tumour Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Bone Tumour
11.1.2.Peripheral Primitive Neuroectodermal Tumour
11.1.3.Askin Tumour
11.1.4.Soft Tissue Tumour
11.2.  Drug Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Vincristine
11.2.2.Cyclophosphamide
11.2.3.Doxorubicin
11.2.4.Etoposide
11.2.5.Ifosfamide
11.2.6.Dactinomycin
11.3.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Chemotherapy
11.3.2.Surgery
11.3.3.Radiation therapy
11.3.4.Others
11.4.  End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital and Clinics
11.4.2.Cancer Treating Centres
11.4.3.Others
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Ewing Sarcoma Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Tumour Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Bone Tumour
12.1.2.Peripheral Primitive Neuroectodermal Tumour
12.1.3.Askin Tumour
12.1.4.Soft Tissue Tumour
12.2.  Drug Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Vincristine
12.2.2.Cyclophosphamide
12.2.3.Doxorubicin
12.2.4.Etoposide
12.2.5.Ifosfamide
12.2.6.Dactinomycin
12.3.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Chemotherapy
12.3.2.Surgery
12.3.3.Radiation therapy
12.3.4.Others
12.4.  End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital and Clinics
12.4.2.Cancer Treating Centres
12.4.3.Others
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Ewing Sarcoma Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Tumour Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Bone Tumour
13.1.2.Peripheral Primitive Neuroectodermal Tumour
13.1.3.Askin Tumour
13.1.4.Soft Tissue Tumour
13.2.  Drug Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Vincristine
13.2.2.Cyclophosphamide
13.2.3.Doxorubicin
13.2.4.Etoposide
13.2.5.Ifosfamide
13.2.6.Dactinomycin
13.3.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Chemotherapy
13.3.2.Surgery
13.3.3.Radiation therapy
13.3.4.Others
13.4.  End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital and Clinics
13.4.2.Cancer Treating Centres
13.4.3.Others
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Ewing Sarcoma Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Tumour Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Bone Tumour
14.1.2.Peripheral Primitive Neuroectodermal Tumour
14.1.3.Askin Tumour
14.1.4.Soft Tissue Tumour
14.2.  Drug Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Vincristine
14.2.2.Cyclophosphamide
14.2.3.Doxorubicin
14.2.4.Etoposide
14.2.5.Ifosfamide
14.2.6.Dactinomycin
14.3.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Chemotherapy
14.3.2.Surgery
14.3.3.Radiation therapy
14.3.4.Others
14.4.  End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital and Clinics
14.4.2.Cancer Treating Centres
14.4.3.Others
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Abbott
15.2.2.AbbVie
15.2.3.Amgen Inc
15.2.4.AstraZeneca
15.2.5.Bausch
15.2.6.Bayer
15.2.7.Bristol-Myers Squibb
15.2.8.Eli Lilly
15.2.9.Merck
15.2.10.GlaxoSmithKline
15.2.11.Johnson & Johnson
15.2.12.Novartis
15.2.13.Sanofi
15.2.14.Pfizer Inc.
15.2.15.F. Hoffmann-La Roche Ltd. (Roche)
16. Research Methodology 
17. Appendix and Abbreviations 
  • Abbott
  • AbbVie
  • Amgen Inc
  • AstraZeneca
  • Bausch
  • Bayer
  • Bristol-Myers Squibb
  • Eli Lilly
  • Merck
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Sanofi
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd. (Roche)

Related Industry Reports